INEX Innovate (or INEX for brief) is Asia’s first ladies’s well being know-how group. As one among Asia’s quickest rising medical know-how builders and medical laboratory operators, INEX focuses on growing and commercialising molecular diagnostic applied sciences within the areas of fetal well being and feminine oncology. With a broad industrial portfolio of validated molecular diagnostic checks for prenatal well being, and girls’s oncology. INEX operates a School of American Pathologists (CAP) accredited scientific laboratory that gives diagnostic testing and contract analysis providers in Singapore to purchasers proper throughout the South East Asian area.

Along with INEX’s rising portfolio of applied sciences which can be below growth, INEX is actively pursuing merger and acquisition alternatives, as a part of a regional rollup technique throughout Asia, with the primary acquisition of a Taiwan genomics enterprise introduced earlier this 12 months. The corporate is exploring additional potential acquisitions in Malaysia, Indonesia and India, with the purpose of making a high two firm in fetal-maternal and girls’s well being diagnostics in Asia. Based by maternal-fetal medication specialists, INEX has been recognised globally with a number of accolades together with The Straits Occasions Singapore’s fastest-growing corporations and the Monetary Occasions’ high-growth corporations Asia-Pacific and has achieved accolades from Frost & Sullivan and the World Mental Property Organisation.

Coming off his latest win on the EY Singapore Entrepreneur of the Yr Awards. LUXUO speaks to INEX Innovate’s chief govt Kane Black on INEX’s position on the way forward for fetal-maternal care and oncology alongside INEX’s ambition to “democratise diagnostics”.

What introduced you into the sector of diagnostic analysis? 

Having been within the life sciences trade for a number of years on the funding facet, diagnostics was a vital half that one among my authentic co-founder’s, Ivanna Salehudin and I, noticed important unmet scientific wants, particularly round ladies’s well being. The significance of diagnostics can’t be overestimated, as with out the provision of correct diagnostics you don’t have remedy. 

This culminated within the institution of Nova Satra Dx Pte Ltd – which started analysis & growth right into a extremely correct liquid biopsy, or blood based mostly, breast most cancers diagnostic check, an organization later backed by Malaysian conglomerate Genting Berhad. In 2019 following a number of conferences with the unique founders of INEX Improvements Change — Prof Mahesh Choolani and Dr. Sidney Yee along with medtech investor Kok Hwee Sim — we noticed a possibility to carry collectively, by the use of a merger, Singapore’s two ladies’s well being life sciences corporations – this led to the creation of what’s now often called INEX Innovate Pte Ltd. 

Since then, the corporate has quickly grown from 10 group members to 55 members, with 35 in Singapore and 20 based mostly in Taiwan. We’ve got launched 11 new lab-based scientific testing providers offering them to a rising community of greater than 200 medical doctors, clinics, and hospitals proper throughout Asia.

INEX now has 34 patents within the ladies’s and maternal well being space and 17 logos, in addition to a variety of copyrights, domains and different mental property (IP) tied to its applied sciences. How necessary is analysis and growth (R&D) in your online business? What proportion of your revenues are reinvested in R&D?  

As a medical innovator, INEX Innovate is deeply concerned in academia and analysis and growth. We not solely assist the native eco system by way of supporting analysis, licensing and commercialising the applied sciences which can be developed by the INEX group but in addition in Singapore’s centres of scientific excellence. INEX additionally supplies the scientific and medical group entry to our applied sciences, I.P and know-hows to innovate and create new merchandise.

When it comes to the share of revenues reinvested in R&D, this has fluctuated dramatically as a consequence of our pivot and deal with COVID-19 testing throughout the pandemic after we targeted all sources in supporting Singapore in COVID PCR testing with R&D taking a again seat. In 2022 and 2023 we refocused on R&D and invested roughly 50 % of revenues in R&D. In a normalised atmosphere usually we’d count on to see 10 to fifteen % of income being invested in R&D.

Registered IP being developed is essential because it supplies the incentives that allow innovators throughout all kinds of industries to undertake the customarily dangerous, troublesome, costly, and time-consuming course of of making new-to-the-world improvements. At the moment we see such intangible belongings, comparable to IP rights, which now command roughly 90 % of the S&P500 market worth in 2020.

Established in Singapore, how has the nation which is understood for supporting quick rising SMEs, helped the expansion of INEX?   

Asia stands as the colourful epicenter of fast-growing markets, charming the eye of companies and traders alike. With a dynamic mix of various cultures, revolutionary applied sciences, and a burgeoning center class, the continent is undeniably the place to be for these in search of unprecedented alternatives. Having lived in Asia for nearly 20 years, in Japan, Hong Kong and now Singapore, it might be, in my view troublesome to discover a higher place to ascertain a enterprise at this time than Singapore. With a well-developed ecosystem, deep pool of expert expertise, high quality manufacturing, the most effective infrastructure on the earth mixed with wonderful assist from governing companies, whereas being in South-East Asia, one of many world’s quickest rising and more and more necessary areas of the world, Singapore has been instrumental within the progress of INEX. 

INEX was based by working towards obstetricians, gynaecologists (OBGYNs) and key opinion leaders in fetal-maternal care and oncology. How has such a debuting line-up in growing the enterprise impacted INEX’s core mission?

The founding genesis of INEX as a ladies’s and fetal maternal well being medical innovator stems from our co-founder Prof Mahesh Choolani’s deep expertise within the ladies’s well being area as a practising OBGYN and pre-eminent key opinion chief within the space of fetal maternal well being. This basis uniquely supplies INEX with deep insights into unmet scientific wants which has led us to many first’s – together with being the primary firm in Asia to launch Non Invasive Prenatal Testing “NIPT” with our iGene® NIPT check, OvaCis® an intraoperative level of care check package for sufferers who current with ovarian cysts and plenty of different applied sciences below growth together with LEXI® a Pre-Natal Diagnostic Check and EpiDx® a blood based mostly breast most cancers screening check. 

You’ve gotten acknowledged a number of instances that INEX’s ambition is to “democratise diagnostics” by making these medical procedures extra correct, obtainable and reasonably priced to the general public. Are you able to elaborate additional there? 

I used the time period “democratise diagnostics” to imply permitting or offering affected person’s with a selection. A selection within the sense that we make diagnostic checks extra correct, which is important for the early analysis of illnesses comparable to most cancers, extra extensively obtainable in order that they’re extra accessible and at a decrease value to communities – this disruption can actually solely be a profit to the societies inside which we stay. 

Our imaginative and prescient is to democratise medical diagnostics to ladies throughout Asia and world wide. Bringing them improved early detection that’s extra accessible, giving ladies and moms better certainty and confidence of their well being and discovering illness early, thereby enhancing their probability of medical success. At INEX, we see each affected person who interacts with our merchandise as a singular being who deserves particular person care and a spotlight. Buyer satisfaction is within the core of our imaginative and prescient and coronary heart of our operations.

INEX’s epiDx® is a patient-friendly possibility that reduces discomfort from customary imaging processes. By utilizing a blood pattern, it shows larger sensitivity and specificity than present strategies. Are you able to tell us how distinctive is that this particular course of out there?

One of many huge points throughout Asia with regards to breast most cancers is the stubbornly low screening participation charges. Principally, ladies who needs to be going for normal screening aren’t. This results in a late-stage breast most cancers analysis when affected person’s outcomes are drastically diminished. By transferring to blood-based breast most cancers screenings on the affected person’s level of care GP, we are going to take away the related discomfort, which ladies usually say they really feel is degrading, and supply better accessibility to encourage breast most cancers screening. 

Moreover, it’s estimated 50 % of Asian ladies have, what is called, dense breast tissue. Dense breast tissue could make irregular findings more durable to see on a mammogram as a result of dense breast tissue and a few irregular breast adjustments, comparable to calcifications and tumours, each seem as white areas within the mammogram.

With this in thoughts we went about seeking to develop a know-how which firstly has improved sensitivity and specificity, secondly eliminated the related discomfort and thirdly was obtainable at the usual level of care – with a view that we may carry into common screening applications ladies who aren’t at the moment present process any type of screening and due to this fact enhance affected person outcomes. 

INEX has carried out substantial research on ovarian cancers. What has been the finds and sensible developments within the labs and on the bottom? 

Ovarian most cancers is the fifth most prevalent most cancers suffered by ladies globally. Whereas that is much less prevalent than different cancers it’s sadly one of many deadliest cancers as a consequence of it generally being identified at a complicated stage, when the possibility of profitable therapy is drastically diminished. 

That is due partially to there being no correct molecular screening check at the moment present to detect early-stage ovarian most cancers, so preliminary ovarian most cancers analysis generally discovered based mostly on signs, comparable to bloating, fatigue, weight reduction, stomach distention, pelvic ache and feeling full rapidly. Sadly, by the point most sufferers with ovarian most cancers see a health care provider, 70 % to 80 % are already late stage. That’s as a result of the signs of ovarian most cancers are so obscure, and sufferers usually expertise them for months earlier than in search of assist.

With this unmet want in tackling ovarian most cancers, the group at INEX have developed two options. The primary is OvaCis® an intra-operative level of care check, that’s used to check if an ovarian cyst is benign or malignant (cancerous). As many as 1 in 10 ladies in some unspecified time in the future of their lifetime will develop an ovarian cyst. Whereas these cysts will, as a rule, show to be benign and can clear up with out therapy, it will be significant that they’re examined. Present observe is what is called a “frozen part” the place a surgeon removes a part of the tissue and sends to a pathologist who freezes the tissue with liquid nitrogen, slices the tissue into sections, after which stains it with particular staining options in order that it may be considered below a microscope. This course of takes as much as an hour and isn’t universally obtainable. INEX’s OvaCis® answer is a extremely delicate and particular, and is made on a lateral movement machine, like a COVID-19 ART check package for ease of use, with out want for classy procedures. It merely makes use of the fluid which is from throughout the cyst, which is then positioned onto the machine and visualised inside quarter-hour to decide if the cyst is benign or malignant. 

Secondly we’re growing a blood-based ovarian most cancers screening check dubbed Xena® – a minimally invasive and environment friendly methodology of screening for ovarian most cancers. Xena® measures the degrees of microRNA within the blood, particularly selecting up an irregular expression of microRNAs which can be correlated with the presence of ovarian most cancers. Xena® is aimed to be launched in late 2024.

You shared that “with a gifted, entrepreneurial and devoted group, we’re on monitor to turning into Asia’s main molecular diagnostic developer”. What’s subsequent on the horizon for INEX, an IPO? 

INEX is increasing each organically, by way of new product launches and new market entry, and thru acquisition. As a part of our pan-Asia roll-up technique we not too long ago introduced the acquisition of a Taiwan based mostly genomics group, that has a rising North Asia enterprise with revenues emanating from Taiwan, Japan and Korea. 

We’re at the moment in negotiations on one other potential acquisition of a agency which is the market chief of their nation in fetal-maternal and girls’s well being testing, moreover we’re exploring different potential synergistic M&A alternatives. With this we purpose to be a top-two participant in each market in Asia in fetal-maternal and girls’s well being. 

We’ve got been actively finding out plenty of potential IPO alternatives right here in Singapore, London, New York and a few of the regional bourses. Nevertheless in mild of the present difficult and sub-optimal circumstances within the IPO market, we’re affected person till a window of alternative opens to progress to an eventual IPO.

You’ve gotten gained the extremely coveted EY Singapore Entrepreneur of the Yr Award for the biotechnology sector in 2022. What have been your ideas on receiving this recognition for the work you and your group have produced?  

Being one among six winners to be chosen by an impartial judging panel from near 140 nominations for the EY Singapore Entrepreneur of the Yr Award 2022 was an extremely proud second for me and my group. On the finish of the day as a frontrunner one can solely be pretty much as good as one’s group and this recognition actually is a credit score to the complete group of devoted, pushed, and good members at INEX Innovate and iGene Laboratory. I’m grateful and honored to function Chief Govt of INEX and iGene.

When you have been to call one mentor who has impressed you in your life and profession, who would that be? 

I’ve learnt and been impressed by many individuals in my life from all totally different walks, from my first Japanese boss to enterprise companions, family and friends. I’m an avid reader of biographies and auto biographies and consider these are sometimes a supply of nice inspiration. You possibly can study, and be impressed by, what has taken somebody 20, 30, 40 or 50 years of expertise in a number of hundred pages.

For extra data on INEX, click on right here. 

For extra on the most recent enterprise reads, click on right here.